公开(公告)号：US20210106669A1

公开(公告)日：2021-04-15

申请号：US16768499

申请日：2018-11-30

申请人： TAKEDA VACCINES, INC.

发明人： Jill A. LIVENGOOD ,  Hansi DEAN ,  Htay Htay HAN ,  Raman RAO ,  Jackie MARKS ,  Gary DUBIN ,  Laurence DE MOERLOOZE ,  Hetal PATEL

IPC分类号： A61K39/12 ,  A61P31/14

摘要： The present disclosure relates to Zika virus vaccines and immunogenic compositions having one or more antigens from a Zika virus (e.g., a Zika virus clonal isolate, a non-human cell adapted Zika virus, etc.), and methods of treatments and uses thereof

公开(公告)号：US20200061151A1

公开(公告)日：2020-02-27

申请号：US16561755

申请日：2019-09-05

申请人： TAKEDA VACCINES, INC. ,  HE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT

发明人： Dan T. STINCHCOMB ,  Claire KINNEY ,  Richard M. KINNEY ,  Jill A. LIVENGOOD

IPC分类号： A61K38/16 ,  A61K31/7048 ,  A61K39/12 ,  A61K31/713 ,  C07K14/005 ,  C07K14/18 ,  C07K19/00 ,  C12N15/09 ,  C12N15/861

摘要： Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.